The invention relates to compounds of formula (I) wherein.....C.....is -CH2- or -CH2-CH2- X is -NH-, -C(0)NH- or -NHC(0)NH- Ar is phenyl or a 5 or 6-membered heteroaryl group containing one or two N atoms R1 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by cycloalkyl, lower alkoxy substituted by halogen or is cycloalkyl -( )- is -CH2- n is 0 or 1 m is 0, 1 or 2 or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinsons disease, neurodegenerative disorders, Alzheimers disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.La presente invención se refiere a los compuestos de la fórmula (I) en donde ----C----- es -CH2- o -CH2-CH2- X es -NH-, -C(O)NH- o -NHC(O)NH- Ar es fenilo o un grupo heteroarilo de 5 o 6 elementos que contiene uno o dos átomos de N R1 es halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por cicloalquilo, alcoxi inferior sustituido por halógeno o es cicloalquilo -( )- es -CH2- n es 0 o 1 m es 0, 1 o 2 o una sal de adición ácida farmacéuticamente adecuada del mismo, todas las mezclas racémicas, todos sus enantiómeros y/o isómeros ópticos correspondientes, tales compuestos pueden ser utilizados para el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención con hiperactividad (ADHD), trast
